ANCN Anchiano Therapeutics Ltd.

1.32
-0.06  -4%
Previous Close 1.38
Open 1.34
Price To Book 1.06
Market Cap 9,803,874
Shares 7,419,870
Volume 8,485
Short Ratio
Av. Daily Volume 37,237
Stock charts supplied by TradingView

NewsSee all news

  1. Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

    CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (NASDAQ:ANCN) (the "Company") announced today that its board of directors approved the record date for the Company's 2020 Annual General

  2. Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (NASDAQ:ANCN) ("Anchiano"), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today

  3. Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs

    Anchiano will make an upfront payment in exchange for the option to in-license at any time through obtaining an Investigational New Drug (IND) designation Company also provides update on accrual to its ongoing pivotal

  4. Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

    CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (NASDAQ:ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial discontinued due to lack of efficacy - November 15, 2019.
Inodiftagene - Codex
Non-muscle invasive bladder cancer (NMIBC)
Phase 3 planned for 4Q 2019 or 1Q 2020.
Inodiftagene with BCG - Leo
Non-muscle invasive bladder cancer (NMIBC)

Latest News

  1. Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders

    CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (NASDAQ:ANCN) (the "Company") announced today that its board of directors approved the record date for the Company's 2020 Annual General

  2. Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (NASDAQ:ANCN) ("Anchiano"), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today

  3. Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs

    Anchiano will make an upfront payment in exchange for the option to in-license at any time through obtaining an Investigational New Drug (IND) designation Company also provides update on accrual to its ongoing pivotal

  4. Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

    CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (NASDAQ:ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat